Swiss dental firm vVardis lands $175 million in New York share sale
Reuters reports Swiss dental firm vVardis raised $175 million in its US share sale, priced below the target range after the offering was downsized.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Zug-based dental company vVardis said on Friday, according to Reuters, that it collected $175 million through its US initial public offering. The firm sold 9.72 million shares at $18 each, below its planned $21–24 range, after cutting the deal from 9.5 million shares.
Pressure on the US listings market is building from an AI-driven tech sell-off, doubts about Nvidia's leadership, and uncertainty over AI rules and data-center spending after Democrats' midterm win. Founded in 2020 by Swiss dentists, vVardis sells non-invasive treatments under the Curodont brand that aim to reverse early tooth decay without drills or needles. US sales of its flagship product jumped 112% in the nine months to September 30, and more than 20,000 dental practices had bought it by June 30.
The Abivardi sisters have additionally put about 10.3 million shares up as security for personal loans, the filing shows.
why it matters
For markets, the weak pricing signals cautious appetite for new listings during a tech sell-off. The regulatory status also matters: Curodont is sold in the US as an over-the-counter drug, and the FDA has not judged its safety or efficacy.
market impact
US IPO market: weak pricing points to cautious demand for new listings.
tags
instruments
sources
- Swiss dental startup vVardis raises $175 million in US IPO — Reuters, 13 November 2026 at 05:11 UTC
- Swiss dental startup vVardis raises $175 million in US IPO — Reuters, 13 November 2026 at 05:33 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗